News

Help shape the UKKA’s direction, represent medical members and contribute to national conversations about kidney care.

Voting is now open for the UKKA Clinical Vice President (Medical) election.

Following review, the MHRA has concluded that the available evidence no longer supports a positive benefit-risk balance for Avacopan Vifor (previously known as Tavneos), used in combination with rituximab or cyclophosphamide for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).

The UK Kidney Association welcomes Ginny Quan and Stephen John as the new Co-Chairs of its Clinical Directors Group.

We are seeking a renal trainee to join the UKKA 'Writing to Kidney Patients' project, which aims to develop national, co-produced resources to make kidney clinic communication genuinely patient-centred rather than clinician- or GP-directed.